C. Loveday

M. Poljak, A. Wensing, R. Paredes, 2016, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.

Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients : A randomized controlled comparison with zidovudine monotherapy

C. Katlama, S. Staszewski, M. Johnson, 1996 .

Effects of salicylates on blood changes in mycoplasma arthritis in rats

C. Loveday, V. Eisen, 1973, British journal of pharmacology.

Blood changes in experimental arthritis in two types of genetically different rats

G. B. West, C. Loveday, V. Eisen, 1973, British journal of pharmacology.

Interventions to prevent vertical transmission of HIV-1: effect on viral detection rate in early infant samples

Christoph Rudin, Marie-Louise Newell, Jack Moye, 2000, AIDS (London).

Safety and efficacy of lamivudine-zidovudine combination therapy in zidovudine-experienced patients : A randomized controlled comparison with zidovudine monotherapy

P. Harrigan, S. Staszewski, M. Johnson, 1996 .

Safety and efficacy of lamivudine-zidovudine combination therapy in zidovudine-experienced patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group.

P. Harrigan, S. Staszewski, C. Loveday, 1996, JAMA.

Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group.

C. Katlama, S. Staszewski, C. Loveday, 1996, JAMA.

Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel.

Victoria A Johnson, Daniel R Kuritzkes, Françoise Brun-Vézinet, 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Drug resistance mutations in HIV-1.

R. Shafer, D. Richman, V. Johnson, 2003, Topics in HIV medicine : a publication of the International AIDS Society, USA.

The Calculated Genetic Barrier for Antiretroviral Drug Resistance Substitutions Is Largely Similar for Different HIV-1 Subtypes

Klaus Korn, Anne-Mieke Vandamme, Sabine Yerly, 2006, Journal of acquired immune deficiency syndromes.

Zidovudine Phosphorylation Determined Sequentially over 12 Months in Human Immunodeficiency Virus-Infected Patients with or without Previous Exposure to Antiretroviral Agents

C. Loveday, D. Back, M. Barry, 2001, Antimicrobial Agents and Chemotherapy.

Sclerosing cholangitis rapidly following anti-HIV-1 seroconversion.

C. Loveday, R. Miller, D. Mercey, 1991, Genitourinary medicine.

Course of Viral Load Throughout HIV‐1 Infection

C. Sabin, A. Phillips, C. Loveday, 2000, Journal of acquired immune deficiency syndromes.

British HIV Association (BHIVA) guidelines for the treatment of HIV‐infected adults with antiretroviral therapy

B. Gazzard, C. Leen, D. Pillay, 2001, HIV medicine.

Multicenter comparison of three commercial methods for quantification of human immunodeficiency virus type 1 RNA in plasma

F. Brun-Vézinet, I. Williams, C. Loveday, 1996, Journal of clinical microbiology.

Effect of cellulose sulphate on serum complement

C. Loveday, V. Eisen, 1970, British journal of pharmacology.

The neuromuscular blocking action of suxamethonium in the anaesthetised rat.

C. Loveday, J. Ireson, R. Ford, 1969, Archives internationales de pharmacodynamie et de therapie.

Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management.

Klaus Korn, Anne-Mieke Vandamme, Sabine Yerly, 2005, The Journal of infectious diseases.

Course of viral load throughout HIV-1 infection.

C. Sabin, A. Phillips, C. Loveday, 2000 .

Immune markers and viral load after HIV‐1 seroconversion as predictors of disease progression in a cohort of haemophilic men

C. Sabin, A. Phillips, C. Loveday, 1998, AIDS.

Tracing the HIV-1 subtype B mobility in Europe: a phylogeographic approach

O. Pybus, A. Wensing, K. Korn, 2009, Retrovirology.

Use of polymerase chain reaction and quantitative antibody tests in children born to human immunodeficiency virus‐1‐infected mothers

C. Giaquinto, C. Loveday, R. Tedder, 1995, Journal of medical virology.

Detection of HIV-1 RNA in factor VIII concentrate.

C. Loveday, R. Tedder, M. Semple, 1991, AIDS.

Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management: recommendations for the European setting

K. Hertogs, F. Brun-Vézinet, D. Pillay, 2001 .

Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management: recommendations for the European setting. The EuroGUidelines Group for HIV resistance.

Soriano, K. Hertogs, F. Brun-Vézinet, 2001, AIDS.

Attitudes of cardiothoracic surgeons in the UK to human immunodeficiency virus

C. Loveday, P. Goldstraw, M. Yacoub, 1992, The British journal of surgery.

Reasons for modification and discontinuation of antiretrovirals: results from a single treatment centre

C. Sabin, A. Phillips, M. Youle, 2001, AIDS.

Evolution of drug resistance in HIV-infected patients remaining on a virologically failing combination antiretroviral therapy regimen

F. Antunes, B. Clotet, L. Ruiz, 2007, AIDS.

Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA

A. Mocroft, O. Kirk, B. Clotet, 2008, AIDS.

Changes in circulating immune complexes during the Jarisch Herxheimer reaction in secondary syphilis

C. Loveday, J. Bingham, 1993, European Journal of Clinical Microbiology and Infectious Diseases.

Replicative fitness in vivo of HIV‐1 variants with multiple drug resistance‐associated mutations

M. Johnson, C. Loveday, V. Emery, 2001, Journal of medical virology.

Relationships among the detection of p24 antigen, human immunodeficiency virus (HIV) RNA level, CD4 cell count, and disease progression in HIV-infected individuals with hemophilia.

C. Sabin, A. Phillips, C. Loveday, 2001, Journal of Infectious Diseases.

Observations of HIV-1 Genotypic Drug Resistance in a Trial of Four Reverse Transcriptase Inhibitors (Quattro Trial)

D. Jeffries, A. Breckenridge, C. Loveday, 2002, Antiviral therapy.

Quantitative differences in the distribution of zidovudine resistance mutations in multiple post‐mortem tissues from AIDS patients

M. Johnson, C. Loveday, P. Griffiths, 1998, Journal of medical virology.

A Randomised Trial of Subcutaneous Intermittent Interleukin-2 without Antiretroviral Therapy in HIV-Infected Patients: The UK–Vanguard Study

R. Davey, H. Lane, M. Youle, 2006, PLoS clinical trials.

Long term probability of detection of HIV-1 drug resistance after starting antiretroviral therapy in routine clinical practice

B. Gazzard, D. Pillay, C. Sabin, 2005, AIDS.

Long‐latency event‐related potentials in asymptomatic human immunodeficiency virus type 1 infection

C. Loveday, B. Sweeney, I. Weller, 1994, Annals of neurology.

Rapid decline in detectability of HIV-1 drug resistance mutations after stopping therapy.

M. Youle, C. Loveday, M A Johnson, 1999, AIDS.

Reduction in human immunodeficiency virus type 1 mutations associated with drug resistance after initiating new therapeutic regimens in pretreated patients.

C. Sabin, M. Youle, C. Loveday, 2000, The Journal of infectious diseases.

In vivo HIV-1 replicative capacity in early and advanced infection.

A. Phillips, C. Loveday, G. Janossy, 1999, AIDS.

HIV-1 Subtypes and Response to Combination Antiretroviral Therapy in Europe

A. Mocroft, L. Ruiz, A. Phillips, 2006, Antiviral therapy.

Theoretical rationale for the use of sequential single-drug antiretroviral therapy for treatment of HIV infection

Caroline A Sabin, Clive Loveday, C. Sabin, 2003, AIDS.

CD4 cell count changes in individuals with counts above 500 cells/mm and viral loads below 50 copies/ml on antiretroviral therapy.

C. Sabin, A. Phillips, F. Lampe, 2002, AIDS.

Extensive antiretroviral therapy resistance in an HIV-infected Zimbabwean patient in the UK.

D. Watson-Jones, C. Loveday, E. Foley, 2003, AIDS.

Substantial correlation between HIV type 1 drug-associated resistance mutations in plasma and peripheral blood mononuclear cells in treatment-experienced patients.

C. Sabin, M. Youle, C. Loveday, 2000, AIDS research and human retroviruses.

The appearance of drug resistance-associated point mutations in HIV type 1 plasma RNA precedes their appearance in proviral DNA.

C. Loveday, M. Tenant‐Flowers, S. Kaye, 1995, AIDS research and human retroviruses.

Baseline Resistance and Virological Outcome in Patients with Virological Failure who Start a Regimen Containing Abacavir: Eurosida Study

O. Kirk, B. Clotet, L. Ruiz, 2004, Antiviral therapy.

Comparative effectiveness of dried plasma HIV-1 viral load testing in Brazil using ViveST for sample collection.

C. Loveday, M. Holodniy, R. Diaz, 2010, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

Lack of suppression by ribavirin of HIV viraemia

C. Loveday, S. Gill, R. Gilson, 1992, The Lancet.

Community-based respiratory viral infections in HIV positive patients with lower respiratory tract disease: a prospective bronchoscopic study.

C. Loveday, R. Miller, J. Holton, 1996, Genitourinary medicine.

Enzyme-linked immunosorbent assays for the measurement of human immunodeficiency virus, type 1 reverse transcriptase antigen and antibodies.

C. Loveday, R. Tedder, R. S. Tedder, 1993, Journal of virological methods.

Resistance and Virological Response Analyses in a Three Initial Treatment Strategy Trial: A Substudy of the INITIO Trial

L. Bacheler, F. Brun-Vézinet, D. Cooper, 2009, HIV clinical trials.

The epic project: developing national evidence-based guidelines for preventing healthcare associated infections. Phase I: Guidelines for preventing hospital-acquired infections. Department of Health (England).

H P Loveday, R J Pratt, N Robinson, 2001, The Journal of hospital infection.

Importance of Baseline Prognostic Factors With Increasing Time Since Initiation of Highly Active Antiretroviral Therapy: Collaborative Analysis of Cohorts of HIV-1-Infected Patients

Anne M Johnson, A. Trkola, J. Sterne, 2007, Journal of acquired immune deficiency syndromes.

Changes in intra-vascular complement and anti-treponemal antibody titres preceding the Jarisch-Herxheimer reaction in secondary syphilis.

C. Loveday, R. Tedder, J. Storey, 1976, Clinical and experimental immunology.

Changes in intravascular kininogen during the Jarisch-Herxheimer reaction in secondary syphilis.

C. Loveday, J. Bingham, 1982, The British journal of venereal diseases.

Phase I/II study of 3TC (lamivudine) in HIV‐positive, asymptomatic or mild AIDS‐related complex patients: sustained reduction in viral markers

C. Robert, C. Loveday, C. Boucher, 1995 .

Adherence to Antiretroviral Therapy: Appropriate Use of Self-Reporting in Clinical Practice

C. Loveday, M. Hankins, P. Franks, 2001, HIV clinical trials.

Changes in CD4 lymphocyte counts after interruption of therapy in patients with viral failure on protease inhibitor-containing regimens

A. Phillips, M. Youle, C. Loveday, 2000, AIDS.

Immunological, virological and clinical response to highly active antiretroviral therapy treatment regimens in a complete clinic population

A. Phillips, M. Youle, C. Loveday, 2000, AIDS.

HIV‐1 dynamics after transient antiretroviral therapy: Implications for pathogenesis and clinical management

A. McLean, A. Phillips, C. Loveday, 1997, Journal of medical virology.

A randomized trial comparing regimens of four reverse transcriptase inhibitors given together or cyclically in HIV-1 infection - The Quattro Trial

D. Jeffries, A. Breckenridge, C. Loveday, 1999 .

HIV results in the frame. Results confirmed.

M A Nowak, S Bonhoeffer, P Balfe, 1995, Nature.

An evaluation of HIV RNA and CD4 cell count as surrogates for clinical outcome. Delta Coordinating Committee and Virology Group.

Abdel Babiker, Philippe Flandre, Peter Reiss, 1999, AIDS.

The sensitivity of HIV-1 DNA polymerase chain reaction in the neonatal period and the relative contributions of intra-uterine and intra-partum transmission

E. Denamur, W. Borkowsky, C. Loveday, 1995 .

Safety, tolerance, and efficacy of atevirdine in asymptomatic human immunodeficiency virus-infected individuals

I. Williams, P. Ward, C. Loveday, 1996, Antimicrobial agents and chemotherapy.

Original article Hepatitis B virus infection in patients attending a genitourinary medicine clinic: risk factors and vaccine coverage

C. Loveday, R. Tedder, R. Gilson, 1998 .

SEROPREVALENCE OF HEPATITIS-B VIRUS-INFECTION IN PATIENTS ATTENDING A GENITOURINARY MEDICINE CLINIC

C. Loveday, G. Kelly, R. Gilson, 1990 .

Neurophysiological assessment of peripheral nerve and spinal cord function in asymptomatic HIV-1 infection: Results from the UCMSM/Medical Research Council neurology cohort

C. Loveday, B. Sweeney, I. Weller, 1995, Journal of Neurology.

Antiretroviral Drug Resistance Testing in Adult HIV-1 Infection

C. Loveday, J. Mellors, L. Demeter, 2000 .

Hepatitis B virus infection in patients attending a genitourinary medicine clinic: risk factors and vaccine coverage.

C. Loveday, R. Tedder, I. Weller, 1998, Sexually transmitted infections.

Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA

A. Mocroft, O. Kirk, B. Clotet, 2008, AIDS.

Raised viral load in patients with viral suppression on highly active antiretroviral therapy: transient increase or treatment failure?

A. Phillips, F. Lampe, M. Youle, 2002, AIDS.

The prevalence of non-B subtype HIV-1 in a London HIV/AIDS outpatient clinic.

A. Phillips, C. Loveday, A. Burke, 1999, AIDS.